Here are four takeaways:
1. Researchers evaluated more than 650 people who began using the drug during a 32-month period.
2. Findings show PrEP is effective in a high-risk population. Many users contracted a number of STDs during the study, but did not contract HIV.
3. The drug can reduce the risk of HIV infection by 92 percent if it is taken correctly.
4. The FDA approved PrEP in 2012 and recommends the drug to groups who engage in high-risk sexual practices.
More articles on infection & quality control:
MRSA infects Washington school — 5 key facts
Age, location affects outpatient orthopedic patient satisfaction: 5 insights
Vaccinated man excreted polio virus for almost 28 years — 5 facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.